Last update June 30, 2015

Алискирена Фумарат

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

At latest update, relevant information on excretion into breast milk was not found.

Because of pharmacokinetic data (wide distribution volume and moderately high molecular weight) excretion into breast milk in significant quantity seems to be unlikely. Based on a low oral bioavailability, concentration in the infant's plasma should be nil or low, except in premature and newborn infants with a increased intestinal absorption capacity.

Alternatives

  • Captopril ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Enalapril ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Methyldopa ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Metoprolol ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Алискирена Фумарат is Aliskiren in Cyrillic.

Is written in other languages:

Group

Алискирена Фумарат belongs to this group or family:

Tradenames

Main tradenames from several countries containing Алискирена Фумарат in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 2 - 3 %
Molecular weight 610 daltons
Protein Binding 47 - 51 %
VD 135 l/Kg
Tmax 1 - 3 hours
T½ 34 - 41 hours

References

  1. EMEA. Aliskireno. Ficha técnica. 2012 Full text (in our servers)
  2. Belda-Rustarazo S, Vallejo-Rodríguez I, Molina-Carballo A, Cabeza Barrera J. Tratamiento de rescate con aliskiren en \ hipertensión maligna familiar en un \ lactante. \ [Salvage therapy with aliskiren in malignant familial hypertension in a breast-fed baby]. Farm Hosp. 2011 Abstract Full text (in our servers)
  3. Belda-Rustarazo S, Vallejo-Rodríguez I, Molina-Carballo A, Cabeza Barrera J. [Salvage therapy with aliskiren in malignant familial hypertension in a breast-fed baby]. Farm Hosp. 2011 Abstract
  4. Waldmeier F, Glaenzel U, Wirz B, Oberer L, Schmid D, Seiberling M, Valencia J, Riviere GJ, End P, Vaidyanathan S. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos. 2007 Abstract Full text (in our servers)
  5. Vaidyanathan S, Jermany J, Yeh C, Bizot MN, Camisasca R. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. Br J Clin Pharmacol. 2006 Abstract Full text (in our servers)

Total visits

1,582

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM